Azithromycin is not associated with QT prolongation in hospitalized patients with community-acquired pneumonia

Pharmacoepidemiology and Drug Safety

Volumn 24, Issue 10, 2015, Pages 1042-1048

  Goldstein, Lee Hilary ^a,b   Gabin, Ahmad ^a   Fawaz, Abdallah ^a   Freedberg, Nahum Adam ^a,b   Schwartz, Naama ^a,c   Elias, Mazen ^a,b   Saliba, Walid ^a,b  

^a HAEMEK MEDICAL CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c UNIVERSITY OF HAIFA   (Israel)

Author keywords

Azithromycin; Hospitalization; Macrolides; Pharmacoepidemiology; Pneumonia; QT prolongation

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZITHROMYCIN; CEFTRIAXONE; CHLORAMPHENICOL; DOXYCYCLINE; ELECTROLYTE; QUINOLONE DERIVATIVE; ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CARDIAC PATIENT; CARDIOVASCULAR MORTALITY; COHORT ANALYSIS; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ELECTROCARDIOGRAM; FEMALE; HIGH RISK PATIENT; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QT PROLONGATION; QTC INTERVAL; RISK FACTOR; CHEMICALLY INDUCED; COMMUNITY-ACQUIRED INFECTIONS; HOSPITALIZATION; LONG QT SYNDROME; PHARMACOEPIDEMIOLOGY; PNEUMONIA, BACTERIAL; STATISTICS AND NUMERICAL DATA;

AGED; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HOSPITALIZATION; HUMANS; LONG QT SYNDROME; MALE; PHARMACOEPIDEMIOLOGY; PNEUMONIA, BACTERIAL; PROSPECTIVE STUDIES;

EID: 84942833839     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3842     Document Type: Article

References (18)

1. Ohatani H, Taniniaka C, Hanada E, et al. Comparative pharmacodynamic analysis of Q-T interval prolongation induced by the macrolides clarithromycin, roxithromycin, and azithromycin in rats. Antimicrob Agents Chemother 2000; 44: 2630-2637.
2. Woywodt A, Grommas U, Buth W, Rafflenbeul W. QT prolongation due to roxithromycin. Postgrad Med J 2000; 76: 651-653.
3. Matsunaga N, Oki Y, Prigollini A. A case of QT-interval prolongation precipitated by azithromycin. N Z Med J 2003; 116: U666.
4. Samarendra P, Kumari S, Evans SJ, Sacchi TJ, Navarro V. QT prolongation associated with azithromycin/amiodarone combination. Pacing Clin Electrophysiol 2001; 24: 1572-1574.
5. Kezerashvili A, Khattak H, Barsky A, Nazari R, Fisher JD. Azithromycin as a cause of QT-interval prolongation and torsade de pointes in the absence of other known precipitating factors. J Interv Card Electrophysiol 2007; 18: 243-246.
6. Russo V, Puzio G, Siniscalchi N. Azithromycin-induced QT prolongation in elderly patient. Acta Biomed 2006; 77: 30-32.
7. Chennareddy SB, Siddique M, Karim MY, Kudesia V. Erythromycin-induced polymorphous ventricular tachycardia with normal QT interval. Am Heart J 1996; 132: 691-6.
8. Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012; 366: 1881-1990.
9. Svanström H, Pasternak B, Hviid A. Use of azithromycin and death from cardiovascular causes. N Engl J Med 2013; 368: 1704-1712.
10. FDA Statement regarding azithromycin (Zithromax) and the risk of cardiovascular death. May 2012. Accessed at: http://www.fda.gov/Drugs/Drugsafety/ucm304372.htm
11. FDA Drug Safety Communication: azithromycin (Zithromax or Zmax) and the risk of potentially fatal heart rhythms. Dec 2013. Accessed at: http://www.fda.gov/Drugs/DrugSafety/ucm341822.htm
12. Mortensen EM, Halm E, Jo Pugh M, et al. Association of azithromycin with mortality and cardiovascular events among older patients hospitalized with pneumonia. JAMA 2014; 311: 2199-2208.
13. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336: 243-50.
14. Bazett HC. An analysis of the time relationships of electrocardiograms. Heart 1920; 7: 355-70.
15. Aliberti S, Ramirez JA. Cardiac diseases complicating community-acquired pneumonia. Curr Opin Infect Dis 2014; 27: 295-301.
16. Corrales-Medina VF, Suh KN, Rose G, et al. Cardiac complications in patients with community-acquired pneumonia: a systematic review and meta-analysis of observational studies. PLoS Med 2011; 8: e1001048.
17. Corrales-Medina VF, Musher DM, Wells GA, et al. Cardiac complications in patients with community-acquired pneumonia. Incidence, timing, risk factors, and association with short-term mortality. Circulation 2012; 125: 773-781.
18. Pasquier M, Pantet O, Hugli O, et al. Prevalence and determinants of QT interval prolongation in medical inpatients. Internal Med J 2012; 42: 933-40.